 | |
| Clinical data | |
|---|---|
| Trade names | Glufast |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | By mouth (tablets) |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C19H25NO3 |
| Molar mass | 315.413 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Mitiglinide (INN,[1] trade nameGlufast) is adrug for the treatment oftype 2 diabetes.[2]
Mitiglinide belongs to themeglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan byKissei andTakeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gainedFDA approval.
Mitiglinide is thought to stimulateinsulin secretion by closing the ATP-sensitive potassiumKATP channels in pancreaticβ cells.
Mitiglinide is delivered in tablet form.
